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Abstract
Background: Major depressive disorder and associated mood syndromes are amongst the most common
psychiatric disorders. To date, electroconvulsive therapy (ECT) is considered the most effective short-term treatment
for patients with severe or treatment-resistant depression. In clinical practice, there is considerable variation in the
ECT dosing schedule, with the number of sessions typically ranging from 6 to 12, with early antidepressant effects
being predictive of increased positive outcomes. We describe here an unusual case of a female patient with severe
depression who did not respond to ECT until the 11th session, after which she had shown a drastic improvement
in her mental state.
Case presentation: A 75-year-old female presented to the old age psychiatry inpatient unit with new onset
dysphoric mood, anhedonia, and severe negativity. She scored 23 on the 17-item Hamilton Rating Scale for
Depression (HAM-D), and was rated 6 on Clinical Global Impression severity (CGIS) by the responsible clinician. She
suffered from post-natal depression fifty years ago and was successfully treated with ECT. She was therefore
initiated on a course of ECT treatment. Her condition initially deteriorated, displaying features of catatonia and
psychosis, unresponsive to ECT treatment or concurrent psychotropic medications. After 11th ECT session, she
started to show signs of clinical improvement and returned close to her baseline mental state after a total of 17
ECT sessions. She remained well 3 months post-treatment, scoring 4 on HAM-D, Clinical Global Improvement or
change (CGI-C) rated as 1 (very much improved). The diagnosis was ICD-10 F32.3 severe depressive episode with
psychotic symptoms.
Conclusions: we describe here an unusual case of delayed response to electroconvulsive therapy in the treatment
of severe depressive disorder. Studies have shown the number of acute ECT treatments to be highly variable,
affected by a number of factors including treatment frequency, condition treated and its severity, the ECT technical
parameters, as well as concurrent use of pharmacological treatment. This may call for re-consideration of the
current ECT treatment guidelines, requiring more research to help stratify and standardize the treatment regime.
Keywords: Electroconvulsive therapy, Major depressive disorder, Delayed response, Standard treatment regime
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: Fangyue.chen@nhs.net
1Peterborough City Hospital, Bretton Gate, Peterborough, UK
Full list of author information is available at the end of the article
Chen et al. BMC Psychiatry           (2021) 21:50 
https://doi.org/10.1186/s12888-021-03053-0
Background
Major depressive disorder (MDD) and associated mood
syndromes are amongst the most common psychiatric dis-
orders. MDD can at times become debilitating, or at
worst, life-threatening. In general, antidepressant medica-
tions can be effective in treating MDD, but they fail to
achieve remission in approximately 1 in 3 patients [1].
Electroconvulsive therapy (ECT) is considered the
most effective short-term treatment for patients with se-
vere or treatment-resistant depression, with 70–90% of
patients showing improvement [2]. ECT involves the ap-
plication of electricity to the scalp in order to induce
seizure activity [3].
There is a considerable variation in ECT dosing
schedules in clinical practice. During an acute course of
the treatment, ECT is given as a twice-weekly regime in
the United Kingdom [4], and twice or thrice-weekly as
recommended in the United States [5]. More frequent
schedule may be given in situations where rapid onset
of response is of prime importance. The number of ses-
sions typically range from 6 to 12 [4]. It has been sug-
gested that individuals with schizophrenia may need 12
to 20 sessions [6]. Rarely, some patients may be pre-
scribed ECT as ‘continuation’ (C-ECT) or ‘maintenance’
ECT (M-ECT) to prevent relapse and recurrence,
respectively [7].
The ECT handbook of the Royal College of Psychia-
trists stated that clinicians may wish to reassess the need
for ECT if there was no response after six sessions. If
there is no response within 12 treatment sessions, it is
unlikely to have a ‘sustained response to ECT [8].’
The number of ECT sessions required to elicit
improvement tends to vary depending on the intensity
of ECT, where a thrice weekly regime yields faster re-
sponse than twice weekly [9]. Other factors associated
with a rapid response include the severity of depression
and seizure Energy Index [10, 11]. The pulse width of
the ECT stimulation and electrode placement have also
been implicated in the speed of response [12, 13]. A few
of the important factors affecting ECT efficacy are sum-
marised in Table 1. One study had concluded that the
average number of sessions required to elicit remission
in depression was 10.9 (± S.D. 4.3) [14]. Another showed
a 50% response rate to ECT after the 12th session [15],
whilst some patients showed response to ECT after the
first session [16]. To date, we are not aware that there is
robust clinical evidence to support using 12 sessions as a
cut-off point, apart from the legal framework of ECT.
Thirtalli et al. reviewed the factors influencing the
number of ECT sessions, from which no recommen-
dations could be drawn, and the number of ECT ses-
sions was not included as primary outcomes in the
reviewed studies [17].
One of the variables predictive of increased positive
outcomes is the early antidepressant effects of ECT. A
study by the Consortium for Research in ECT has indi-
cated that more than half of patients treated with ECT
showed improvement after 3 sessions, and 65% achieved
remission after 10 sessions [16]. Likewise, Tsuchiyama
et al. 2005 reported that response by session 3 of ECT
treatment predicted long-term efficacy in relieving
depression [18]. On the contrary, a study examining the
effectiveness of ECT in adolescents suggested that early
lack of response does not necessarily predict a lack of
response at the end of the ECT course, with significant
clinical improvement seen after 12 sessions [19].
In this article, we outline a case of a female patient,
who presented with severe depressive episode. She
initially failed to respond to her ECT treatment, until
the 11th session, when she had a drastic improvement in
her clinical presentation.
Case presentation
A 75-year-old female patient presented to the old age
psychiatry inpatient unit with a 10-week history of
deteriorating depressive symptoms, triggered by a
telephone scam. She had repeatedly attempted to slit
her wrists with a knife, and developed concerns about
Table 1 Factors associated with ECT efficacy
Factors Associations Ref.
ECT intensity Thrice weekly ECT yields faster response than twice weekly, but induced more severe memory impairment [9]




The presence of psychotic features predicts ECT remission [11]
Seizure energy index (SEI) High SEI is associated with a rapid response [10]
Age Older age predicts faster speed of response [11,
12]
Pulse width Brief pulse ECT (pulse width 1.0 ms) is associated with higher remission rates than ultrabrief pulse (pulse width
0.3 ms)
[12]
Electrode placement Bilateral electrode placement is more efficient than alternative electrode placement [13]
Chen et al. BMC Psychiatry           (2021) 21:50 Page 2 of 9
having cancer following two brief illnesses with infec-
tions. On admission, she presented with dysphoric
mood, anhedonia, and severe negativity. She described
herself as not having ‘any thoughts in my head,’ and
‘frightened.’ She showed evidence of catastrophizing,
and appeared hypervigilant. Her food and fluid intake
had been poor over the past 10 weeks.
In the past, she suffered from post-natal depression
fifty years ago and was successfully treated with ECT. In
the intervening years, she did not suffer from any epi-
sodes of severe mental illness, with no depression or
mania. Physically, she suffered from hypertension, type 2
diabetes mellitus, chronic obstructive pulmonary disease,
and polymyalgia rheumatica for which she was on a
reducing dose regime of prednisolone (4 mg OD on
admission, reduced by 1 mg every 12 week). She was a
non-smoker, and there was no history of alcohol or sub-
stance misuse. She lives with her husband and has two
supportive children living nearby.
On examining her mental state, she was catatonic, dis-
playing excessive motion intermittently including bilat-
eral non-Parkinsonian motion of the upper limbs and lip
licking. Her speech was slow and interrupted in flow.
She felt low in mood and was negative in her outlook.
She was not formally thought disordered, and she was
cognitively intact. She had insight into the deterioration
of her mental state and agreed to informal admission to
the hospital for assessment and treatment.
Admission blood tests were normal. She was not an-
aemic, thyroid function tests were normal.
Initially on the ward, she appeared settled and was able to
hold conversations with others. She was periodically anxious,
requiring encouragement with food and drink intake. Due to
her good response previously, the treatment team arranged a
course of ECT during the admission, and she was deemed to
have capacity to consent to the treatment. Prior to starting
ECT, a 17-item Hamilton Rating Scale for Depression
(HAM-D) was obtained, for which she scored 23, indicative
of severe depression. A Mini-mental state examination
(MMSE) was performed, when converted into Adden-
brooke’s Cognitive Examination III (ACE-III), gives 69–73/
100. Clinical Global Impression Severity (CGIS) by the
responsible clinician was rated 6 (severely ill).
ECT was performed with Thymatron® System IV,
using bitemporal electrode placement with a pulse width
of 0.50 millisecond. The details of each ECT session are
summarised in Table 2 and Fig. 1.
Unfortunately, whilst on the ward, her clinical condi-
tion deteriorated. Her catatonia worsened considerably.
She displayed virtually no interaction with external
world. She showed mutism, fixed, non-reactive gaze. At
times she would whisper ‘locked in,’ ‘I can’t’. She repeat-
edly exhibited a rocking motion of her torso with mild
rigidity of her limbs. She was unable to be encouraged
off her armchair and was unable to walk. She was unable
to eat and drink, and was often unable to take oral medi-
cations. Prior to the second planned treatment, the team
felt that she lacked capacity to consent to further
sessions.
A Mental Health Act Assessment was arranged, and
she was detained under Mental Health Act Section 2.
Urgent ECT was prescribed under section 62, whilst a
second opinion appointed doctor (SOAD) was sought
for to grant her further ECT sessions. A total of 12 ECT
sessions were granted.
After eight further sessions, the patient’s mental state
did not improve. She continued to display minimal
engagement. She often refused her medications, and her
food and fluid intake was minimal. As a result, she
underwent intravenous fluid therapy several times due
to dehydration causing a deterioration of renal function.
Treatment was given under Mental Health Act 1983
(amended 2007).
After 4th and 8th ECT sessions, repeated attempts
were made by the ECT doctor to perform a MMSE, but
she was deemed too unresponsive to answer the
questions.
At the same time, several psychotropic medications
were trialled. The date of their commencement and dose
changes in relation to her ECT treatment are sum-
marised in Table 3.
As a result of her lack of response to treatment, her
diagnosis was reviewed and affirmed by the treatment
team. Six further ECT sessions were granted through a
Second Opinion Appointed Doctor (SOAD).
After 11 ECT sessions, she started to show signs of
improvement. She started to walk around the ward and
engage in various group activities. She started to accept
her medications with less prompting. Her food and
drink intake improved significantly, and she could eat
independently. Her engagement with staff gradually
improved, from making appropriate facial expressions to
starting verbal communication. By the end of her ECT
course, she could spontaneously engage in conversations
and reported to us that ‘I am back.’ She was able to
reflect on how severely unwell she was and felt ready to
be discharged home. In view of her clinical improve-
ment, ECT treatment was stopped. Extracts of clinical
documentation on her progress have been summarized
in Table 4.
The diagnosis was made during the admission – ICD-
10 F32.3 severe depressive episode with psychotic symp-
toms [20]. She showed features of psychosis during the
admission period. She frequently appeared guarded and
suspicious, at time frightened. She at times reported that
‘people on the ward were not eating or drinking,’
Three months post-treatment, she scored 4 on HAM-
D, and scored 89–93/100 for ACE-III (converted from
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177.7 0.91 30 0.50 6.5 Not
observed







































9 BL T6 55% 280.3 0.91 40 0.50 7.7 25 41 Propofol 80 mg
Suxamethonium
40mg
10 BL T6 55% 282.7 0.92 40 0.50 7.7 10 29 Propofol 80 mg
Suxamethonium
35mg





12 BL T6 75% 379.0 0.90 60 0.50 7.0 20 30 Propofol 80 mg
Suxamethonium
Chen et al. BMC Psychiatry           (2021) 21:50 Page 4 of 9





























13 BL T6 75% 378.0 0.90 60 0.50 7.0 9 27 Propofol 80 mg
Suxamethonium
40mg
14 BL T6 75% 377.6 0.90 60 0.50 7.0 20 26 Propofol 80 mg
Suxamethonium
40mg
15 BL T6 75% 377.6 0.90 60 0.50 7.0 5 19 Propofol 80 mg
Suxamethonium
40mg
16 BL T6 75% 380.4 0.91 60 0.50 7.0 11 33 Propofol 100 mg
Suxamethonium
40mg
17 BL T6 75% 380.2 0.91 60 0.50 7.0 15 17 Propofol 100 mg
Suxamethonium
40mg
18 Cancelled due to pyrexia of 37.7 C° pre-ECT. COVID-19 was
suspectedb.
aECT dose at which a seizure response is visualised
b2019-nCoV RNA Not Detected
BL/UL bilateral/unilateral temporal electrode placement, GTCS generalized tonic-clonic seizure, EEG electroencephalogram
Fig. 1 ECT session visual and EEG seizure duration in s, charge delivered in mC
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MMSE). Clinical Global Improvement or change (CGI-
C) was rated 1 (very much improved). Efficacy index was
rated at 02 (vast improvement with side effects that do
not significantly interfere with patient’s functioning).
Discussion and conclusion
We describe here a patient with a diagnosis of severe
depression. She did not respond to electroconvulsive
therapy until the 11th session, after which she had
shown a drastic improvement in her mental state. The
case is considered unusual. In the literature, the number
of sessions during an acute course of ECT typically
ranges from 6 to 12, usually given twice a week [4]. Early
antidepressant effects of ECT is predictable of increased
positive outcomes (6–7). Rarely, individuals with schizo-
phrenia may require 12 to 20 sessions to elicit a
response to treatment [5].
Compared to pharmacological treatment, ECT remains
the most effective short-term treatment for patients with
severe or treatment-resistant depression, with 70–90% of
patients showing improvement [2]. In this case, a longer
course of ECT has likely contributed to the patient’s
response and remission.
There may be some debate surrounding the initiation
of the ECT course in this patient. The empirical titration
method aims to establish seizure threshold in the first
session (titration session), and from session two
onwards, therapeutic sessions are given with the stimu-
lus at 1.5 times of the seizure threshold [8]. However,
there has been questions surrounding the current
threshold titration method of being too uncertain for
valid optimisation or individualization of dose [21]. In
this patient, the dose was not up-titrated, given the
adequate seizure duration, good quality EEG fit during
session one, balanced with potential cognitive side effect
in this 75-year-old patient.
Other factors that might have contributed towards the
improvement in this patient’s mental state includes a
change in her medication regime. By the 10th session,
she was taking three adjunctive pharmacological treat-
ments including quetiapine, olanzapine, and lamotrigine.
Quetiapine has demonstrated up to 48% response rate in
combination with SSRIs and have been approved for ad-
junctive treatment of MDD by the Food and Drug Ad-
ministration (FDA) [22]. Olanzapine, when combined
specifically with fluoxetine, demonstrated 60% response
amongst patients with treatment-resistant depression
[23]. Lamotrigine is an anti-convulsive treatment that is
currently licensed as an adjunctive therapy of bipolar
disorder [24]. However, it was introduced by the treat-
ment team following a lack of clinical response from the
other agents and concurrent ECT treatment. Several
studies have shown clinical improvement after augmen-
tation with lamotrigine in treatment-resistant unipolar
depression [25, 26].
The anti-epileptic effect of lamotrigine can theoretic-
ally inhibit the efficacy of ECT in inducing seizure activ-
ity. However, case reports/series have shown minimal or
no influence on seizure and/or seizure duration [23]. In
this patient, there was an increase in seizure threshold at
session 12, with the introduction of lamotrigine being
one possible contributing factor. However, it more than
likely reflected the natural course of an ECT treatment
regime. In addition, sertraline and olanzapine can theor-
etically lower seizure threshold, and some data have sug-
gested beneficial and additive efficacy of second-
generation antipsychotics (SGAs) to ECT, notably with
clozapine [27].
The ECT handbook of the Royal College of Psychia-
trists stated that clinicians may wish to reassess the need
for ECT if there is no response after six sessions. If there
is no response within 12 treatment sessions, the patient
is unlikely to have a ‘sustained response to ECT’ [8].
This patient displayed a delayed response, which is an
Table 3 Timing of medication changes in relation to ECT
sessions over the admission period
Day of stay ECT Session Medication Changes




D17 Sertraline increased to 200mg OD
D18 Session 4
D22 Session 5
D24 Quetiapine 50mg BD
D25 Session 6
D28 Session 7
D31 Quetiapine increased to 75 mg BD
D32 Session 8
D34 Session 9
D35 Quetiapine increased to 100mg BD
D39 Session 10 Lamotrigine 25 mg OD started
D40 Quetiapine stopped. Olanzapine 5 mg
OD started
D42 Session 11
D45 Olanzapine increased to 7.5 mg OD
D46 Session 12
D49 Session 13
D53 Session 14 Lamotrigine increased to 50 mg OD
D56 Session 15
D60 Session 16 Lamotrigine increased to 75 mg OD
D63 Session 17
D67 Lamotrigine to 100mg OD
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Table 4 Patient progress on the ward as documented in the electronic note system
ECT
Session
Prior to ECT Post ECT in recovery Progress on the ward
1 Settled, anxious at times, joined in with
activities.
Able to hold a conversation
Consented to ECT.
Quiet on arrival, but did answer 4/5
orientation questions correctly
Anxious, quiet, but pleasant on approach.
Compliant with medications
Reported to be highly anxious, kept saying
‘no’ or ‘I don’t know’ – unable to give
capacitous consent.
Moderate evidence of psychomotor
retardation and evolving mutism. Did not
appear to be responding to unseen external
stimuli. She required full support for her
personal care
2 Unable to consent On return to the ward, she refused
medications, spitted them out and had her
mouth closed
Poor oral and fluid intake, received IV fluid
treatment due to dehydration and
deteriorating renal function
3
4 Very anxious and unable to answer any of
the orientation questions
Able to drink full cup of squash and ate 2
biscuits. Completed 4/5 orientation questions
Upon returning to the ward, she became
very anxious and hardly communicative. She
was visibly shaking and humming
5 Very anxious and unable to answer any of
the orientation questions
Intermittent compliance with prescribed oral
medication
6 Remained anxious and reluctant. Unable to
answer any questions
Had half a beaker of squash and IV
Hartmann’s. Unable to obtain MMSE
Minimally interactive, and will respond with
single words (no, no, no)
7 Had to be brought on a trolley due to high
level of anxiety, distress and agitation
Had some tea and biscuits – couldn’t answer
orientation questions afterwards
She was having minimal conversation and
continued to say ‘no, no, no.’
8 Very anxious and was reluctant. Unable to
answer any of the orientation questions
Had a mug of tea 280mls as well as 500 ml of
Hartmann’s Fluid IV
She has been keeping tablets in her mouth
at times.
Staff had to escort her to the toilet using a
wheelchair
9 After the session, had tea, toast and biscuit.
Conversed with staff about dieting, exercise
and dogs
She returned to the ward with a smile. Then
in the afternoon, she returned to the anxious
state. She did manage all her meal
10 She had been variable in presentation.
When she is less anxious, she could feed
herself. Other times, she refused to eat and
drink
She had been sat in the communal area
post-ECT.
She was reasonably settled but gradually got
anxious and had been repetitive and making
sounds
11 SOAD applied for 6 further ECT sessions She was very calm, however did not interact
with staff other than with short answers. She
accepted a mug of tea and one and half
slices of toast and marmalade. She was
unable to answer any of the orientation
questions
She has been out in the garden for a walk.
She joined in the colouring group and
participated well. Accepted medication with
less prompting
12 After the treatment, she was much calmer,
however appeared confused at times. She
had tea, cheddars and toast
She engaged well in physiotherapy strength
and balance sessions
13 Calm. Did not answer any of the orientation
questions. The only thing she said was ‘what
is my name.’ She walked calmly back to the
ward with staff
Eating and drinking well. Taking food in the
canteen now, despite eating slowly. Minimal
assistance required with personal care
14 Accepted tea and toast. She was able to
answer 2/5 of the orientation questions,
however did say ‘my name used to be …’
She had been settled and calm, spent time
in communal area with others. She engaged
well when spoken to and has not been
making any noise.
15 She was able to tell us her name, date of
birth, however followed each answer by ‘well
it used to be’
When staff talked to her, she would always
respond back with talking to staff. At times,
she did smile to staff
16 She was able to walk to the clinic with a
member of staff and answered 3/5 of the
orientation questions. She became
increasingly anxious when being prepared
for ECT, however remained cooperative
throughout
She was able to tell us her name and date of
birth, but responded ‘I have no idea’ when
asked where she currently is
Walked back to the ward with no concerns
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exception to the typical response pattern to ECT treat-
ment for major depressive disorder. However, studies
have shown the number of acute ECT treatments to be
highly variable, and its efficacy is affected by a number
of factors including treatment frequency [9], condition
treated and its severity [10], the ECT pulse width [12]
and electrode placement [13]. The concurrent use of
pharmacological treatment for psychiatric and non-
psychiatric conditions can also interact with ECT treat-
ment [27]. This may call for a re-consideration of the
ECT treatment regime, especially in cases where re-
sponse may not have been observed by the later part of
a treatment course. Moreover, further research is needed
to help stratify and standardize the ECT treatment
regime.
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